Insiders · ERNA

ERNA insider transactions

Ernexa Therapeutics Inc. (ERNA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

ERNA insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Ernexa Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Robert J. SpiegelDirector, since September 2026
• James Arthur BristolDirector, since October 2023
• Peter CicalaDirector, since February 2024
• William A. WexlerDirector, since June 2022
• David PolinskyDirector, since August 2026
• Sanjeev LutherPresident and CEO, Director, since January 2024
• Elena RatnerDirector, since January 2025
• Charles Cherington10% owner, since March 2021+$5.47M
• Sandra M GurrolaSr. VP of Finance, since June 2021
• Dorothy J ClarkeGeneral Counsel, Director, since August 2023
• Freebird Partners LP10% owner, since April 2023
• Brant BinderInsider, since July 2023
• Richard W WagnerInsider, since July 2023
• Matthew AngelOfficer, Director, since May 2022
• Nicholas Jason SingerDirector, since March 2021+$929K
• John D Halpern10% owner+$1.1M
• Roger SidhuOfficer, since September 2021
• Gregory FioreDirector, since June 2022
• Kevin DAmourOfficer, since June 2021
• Andrew C. JacksonOfficer, since May 2022
• Howard J. FederoffOfficer, Director, since April 2021
• Jay SialOfficer, since July 2021
• Erin S. EnrightDirector, since January 2022
• Heather B RedmanDirector, since January 2022
• Erich MohrDirector, since May 2021
• Luba GreenwoodDirector, since March 2021
• Dennis LangerDirector, since May 2021
• George P Denny III10% owner, since March 2021+$40.45-$1.2M
• Yiannis MonovoukasDirector, since March 2021
• Ronald GuidoOfficer, since March 2021
• Lynn Sadowski MasonOfficer, since March 2021
• Allen WolffOfficer, Director

Recent Form 3, 4, and 5 filings for ERNA

• 49d
  SEC Form 3 filed by new insider Spiegel Robert J.

  3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by Director Bristol James Arthur

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by Director Cicala Peter

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by Director Wexler William A.

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by Director Polinsky David

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by Director Ratner Elena

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 70d
  SEC Form 4 filed by President and CEO Luther Sanjeev

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 75d
  New insider Polinsky David claimed ownership of 8,000 shares (SEC Form 3)

  3 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 266d
  Large owner Cherington Charles bought $2,000,000 worth of shares (4,000,000 units at $0.50), increasing direct ownership by 144% to 6,779,440 units (SEC Form 4)

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 491d
  Sr. VP of Finance Gurrola Sandra M converted options into 30 shares, increasing direct ownership by 38% to 110 units (SEC Form 4)

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 517d
  Large owner Cherington Charles bought $2,221,826 worth of shares (21,241,163 units at $0.10), increasing direct ownership by 104% to 41,659,743 units (SEC Form 4)

  4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 552d
  Amendment: Large owner Cherington Charles bought 13,252,112 shares, increasing direct ownership by 2,381% to 13,808,577 units (SEC Form 4)

  4/A - Ernexa Therapeutics Inc. (0000748592) (Issuer)
• 586d
  Large owner Cherington Charles bought $394,174 worth of shares (3,768,397 units at $0.10), increasing direct ownership by 23% to 20,401,602 units (SEC Form 4)

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 638d
  SEC Form 4 filed by Director Wexler William A.

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 638d
  SEC Form 4 filed by Sr. VP of Finance Gurrola Sandra M

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 638d
  SEC Form 4 filed by Director Bristol James Arthur

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 638d
  SEC Form 4 filed by Director Cicala Peter

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 638d
  SEC Form 4 filed by President & CEO Luther Sanjeev

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 665d
  SEC Form 4 filed by Director Ratner Elena

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 665d
  SEC Form 3 filed by new insider Ratner Elena

  3 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 735d
  Large owner Cherington Charles bought 13,252,112 shares and converted options into 2,819,546 shares, increasing direct ownership by 2,888% to 16,628,123 units (SEC Form 4)

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 868d
  Sr. VP of Finance Gurrola Sandra M converted options into 437 shares and covered exercise/tax liability with 180 shares, increasing direct ownership by 28% to 1,185 units (SEC Form 4)

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 925d
  SEC Form 4 filed by Cicala Peter

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 925d
  SEC Form 4 filed by Bristol James Arthur

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)
• 925d
  SEC Form 4 filed by Gurrola Sandra M

  4 - Eterna Therapeutics Inc. (0000748592) (Issuer)